Wision AI, Ltd.

Wision AI, Ltd. is an innovative company specializing in digital health solutions that enhance clinical practices, with a strong emphasis on oncology diagnostics. Wision AI, Ltd. focuses on developing advanced healthcare technologies.

Founded in 2016 in Shanghai, China, the company has undergone a strategy to concentrate on oncology solutions. The CEO, Liu Jingjia, has a history in the tech sector, and the company has successfully completed 2 deals, with the most recent funding round in July 2018, aimed at expanding its product offerings. Wision A. I.

specializes in developing advanced digital health solutions focused on enhancing clinical practices, particularly in oncology. Their flagship products include the EndoScreener, an AI-aided diagnostic tool for gastrointestinal endoscopy, and PathoCruz 3D, an automated histological 3D reconstruction tool for localizing cancerous regions in Whole Slide Imaging (WSI). These products are designed to improve diagnostic accuracy in clinical imaging settings, primarily targeting healthcare providers in North America, Europe, and select Asian markets, utilizing small datasets and advanced algorithms to optimize medical diagnosis. Wision A.

I. generates revenue through product sales and partnerships with healthcare institutions. Their key products, including the EndoScreener and PathoCruz 3D, are sold directly to hospitals and diagnostic centers, with pricing structures tailored to specific client needs, potentially involving one-time licensing fees or subscription models for ongoing support. The company's compliance with CE-MDR Mark and FDA 510K for the EndoScreener enhances its marketability among healthcare professionals.

Wision AI, Ltd. aims to launch new products designed to further enhance diagnostic capabilities in oncology. Following their Series A funding round in July 2018, the company plans to expand into new markets, specifically targeting additional regions in Asia and enhancing its presence in North America and Europe. The funding will support product development and market expansion efforts, which are anticipated to drive future growth.